Anorexia nervosa is marked by a persistent restriction of energy intake, an intense fear of weight gain, and a distorted body image, resulting in dangerously low body weight. Despite state-of-the-art treatments aimed at restoring healthy body weight, relapse rates remain alarmingly high—up to 50% within a year post-treatment. Suicidal behavior is also a significant concern, often cited as the leading cause of death among afflicted individuals. This desperate clinical landscape underscores the urgent need for objective biomarkers and more profound mechanistic insights to improve therapeutic outcomes.

The inadequacy of current understanding centers around a crucial chasm: while physicians focus on weight normalization, many patients continue to suffer from entrenched symptoms that drive relapse, suggesting that the disorder’s etiology extends beyond mere weight regulation. The nervous system’s interpretation and integration of visceral signals, especially from the gut, could hold the key to these persistent challenges. Yet, before this study, precise tools to quantify and manipulate these signals in vivo remained elusive.

The UCLA research team harnessed a clinical trial design involving an ingestible vibrating capsule capable of delivering controlled, gentle mechanical stimuli to the stomach. This non-invasive method allowed for real-time interrogation of gastrointestinal interoception—the brain’s perception and processing of internal bodily sensations. By remotely activating the capsule, the researchers could produce varying intensities of stomach vibrations, simulating subtle gut sensations that are typically difficult to access or measure reliably.

In the study, 62 female patients who had been hospitalized for anorexia nervosa and whose body weight had been restored to clinical norms, were compared against 57 healthy controls. Participants swallowed the vibrating capsule and were instructed to indicate, via button press, whenever they perceived a vibration. Concurrent physiological monitoring tracked brain activity through neuroimaging techniques, cardiac rhythms, and stomach motility, providing a multidimensional understanding of the gut-brain axis in real time. Self-reported metrics on hunger and bodily awareness further enriched the dataset.

Employing sophisticated computational modeling, the researchers analyzed participants’ ability to detect and interpret the gastric signals. These models were designed to estimate participants’ expectation of gut sensations, their reliance on incoming sensory signals, and their adaptability in updating these expectations when signals fluctuated. This approach transcended simple sensory detection, probing fundamental cognitive processes involved in interoceptive learning and prediction error correction.

The results revealed a striking divergence between anorexia nervosa patients and healthy controls. Those with the disorder exhibited diminished accuracy in sensing subtle stomach vibrations, often unaware that a stimulus was occurring even when the capsule was active. They demonstrated a cognitive bias towards expecting an absence of gut sensations and were significantly slower to revise these expectations in the presence of confirmed visceral signals. This implies an altered central processing mechanism rather than a peripheral sensory deficit, reflecting a disconnection or miscommunication within the gut-brain axis.

Crucially, these interoceptive abnormalities persisted despite the restoration of healthy body weight, challenging the conventional clinical assumption that weight normalization is tantamount to recovery. The findings suggest that long-lasting neurobiological alterations in interoceptive processing may underlie the stubborn persistence of anorexic behaviors and cognitions, thus offering a plausible explanation for the high relapse propensity witnessed in clinical practice.

Linking these mechanistic insights to clinical outcomes, the study reported a robust association between impaired gastric signal detection and relapse risk during a six-month post-discharge follow-up period. Patients whose nervous systems exhibited the greatest bias towards ignoring bodily signals were significantly more likely to experience a relapse. This highlights the potential clinical utility of the vibrating capsule as a predictive tool, enabling healthcare providers to stratify relapse risk and tailor interventions accordingly.

From a translational perspective, the use of this ingestible technology marks a seminal advance in biomarker discovery for anorexia nervosa. It opens new avenues for personalized medicine where objective physiological metrics, rather than solely subjective symptom reports, guide therapeutic decisions. Moreover, it positions gastrointestinal interoception as a critical target for future treatment strategies, including neuromodulation, pharmacotherapy, and cognitive retraining designed to recalibrate gut-brain communication pathways.

Nevertheless, the authors caution that these findings currently pertain to a relatively homogeneous sample, primarily young female patients, and must be validated across larger and more diverse populations to confirm generalizability. Future research should also explore how different treatment modalities influence interoceptive processing and whether modulation of this axis can directly mitigate relapse risks.

In conclusion, this UCLA-led study redefines our understanding of anorexia nervosa by exposing the subtle but profound alterations in gastrointestinal interoception that endure beyond weight restoration and presage relapse. It suggests that true recovery necessitates healing not only the body but the fundamental neural processes that govern the perception and integration of internal bodily states. This insight sets the stage for an era where interoceptive biomarkers and bioelectronic medicine intersect to revolutionize the management of this devastating disorder.

Subject of Research: Gastrointestinal interoception and relapse prediction in anorexia nervosa
Article Title: Altered Gastrointestinal Interoception in Anorexia Nervosa Predicts Relapse
News Publication Date: 17-Jun-2026
Web References: http://dx.doi.org/10.1001/jamapsychiatry.2026.1301
References: Published in JAMA Psychiatry, 2026
Keywords: Anorexia nervosa, gastrointestinal interoception, relapse prediction, gut-brain axis, ingestible vibrating capsule, psychiatric biomarkers, neurobiology of eating disorders

Hemispheric lateralization—the phenomenon whereby certain cognitive processes or neural functions tend to be more dominant in one hemisphere of the brain than the other—has long intrigued neuroscientists. Traditionally viewed as a relatively stable trait, this study challenges that notion by demonstrating that lateralization patterns in individuals with MDD are far from static; they demonstrate remarkable dynamism that correlates with fluctuations in neurotransmitter systems and genetic expression. Such insights necessitate a paradigm shift, encouraging scientists and clinicians alike to consider temporal variability in brain lateralization when evaluating depressive pathology.

The DIRECT consortium’s study leveraged advanced neuroimaging techniques, including functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), to capture high-resolution snapshots of brain activity across emotional and cognitive tasks tailored to probe lateralized functions. Concurrently, cerebrospinal fluid (CSF) and plasma analyses provided detailed profiles of neurotransmitter concentrations, such as serotonin, dopamine, and gamma-aminobutyric acid (GABA), which are critically implicated in MDD. By integrating genetic sequencing and transcriptomic data, the researchers added an additional layer of understanding regarding how genetic variants may influence lateralization dynamics.

One of the study’s ground-breaking revelations is the observation of fluctuating patterns of lateralization in brain regions traditionally associated with mood regulation, particularly the prefrontal cortex and the anterior cingulate cortex. Contrary to the prevailing assumption of hemispheric dominance existing as a fixed attribute, patients with MDD exhibited periods of transient shifts in dominance from the left to the right hemisphere or vice versa. These shifts were not random but were significantly correlated with the temporal changes in neurotransmitter activity, especially serotonin modulation, reinforcing the biochemical sensitivity of lateralized neural circuits.

Genetic analyses further enriched the narrative by identifying polymorphisms in genes related to neurotransmitter synthesis, receptor density, and synaptic plasticity that modulate hemispheric lateralization’s intensity and directionality. Notably, variants in the serotonin transporter gene (SLC6A4) and dopamine receptor genes (DRD2 and DRD4) emerged as significant predictors of lateralization dynamics. These findings suggest that an individual’s genetic makeup might predispose them to particular lateralization profiles, which in turn could influence their susceptibility to depression or responsiveness to treatment.

The brain’s hemispheric asymmetry plays a pivotal role in emotional processing, with certain theories attributing the left hemisphere to positive affect and approach behaviors, while the right hemisphere is more engaged in negative affect and withdrawal behaviors. The DIRECT consortium’s findings enrich this framework by suggesting that abnormal or fluctuating lateralization may underlie mood instability characteristic of MDD. The dynamic shifts in lateralization might manifest as impaired emotional regulation or heightened susceptibility to stressors, reflecting the biochemical and genetic milieu.

Furthermore, the study highlights the potential for lateralization patterns to serve as biomarkers for MDD subtypes. Patients exhibiting persistent right-hemisphere dominance alongside certain neurotransmitter imbalances and genetic markers might represent a distinct clinical phenotype, potentially resistant to conventional therapies. This stratification could facilitate personalized treatment approaches, including targeted neuromodulation techniques such as transcranial magnetic stimulation (TMS), which could be optimized based on individual lateralization profiles.

Beyond static diagnosis, longitudinal tracking of hemispheric lateralization dynamics emerges as a promising tool for monitoring disease progression and therapeutic efficacy. The incorporation of real-time functional neuroimaging and biofluid assays in clinical settings could enable clinicians to anticipate mood shifts, adjust treatments proactively, and improve patient outcomes. This represents a substantial leap toward precision psychiatry where treatment is tailored not merely to symptom clusters but to the neurobiological states that wax and wane over time.

Another intriguing aspect unearthed by the investigators concerns the interplay between environmental factors and molecular mechanisms influencing lateralization. Stress exposure, for instance, appeared to exacerbate lateralization fluctuations through epigenetic modifications that affect neurotransmitter-related gene expression. This finding underscores the complex gene-environment interactions driving MDD pathophysiology and suggests that therapeutic interventions may need to incorporate strategies to mitigate environmental impacts on brain lateralization.

Moreover, the biophysical mechanisms governing hemispheric lateralization extend to synaptic plasticity and network connectivity alterations observed in depressive states. The study demonstrated disrupted communication within fronto-limbic circuits correlating with lateralization shifts, highlighting the importance of neural network integrity in maintaining stable affective states. Modulations in neurochemical milieu, driven by individual genetic predispositions, appear to precipitate transient decoupling or hyperconnectivity between hemispheres—conditions that may potentiate depressive symptomatology.

The implications of these findings also ripple into the developmental trajectory of MDD. Identifying lateralization patterns and their molecular correlates early in life could enable preemptive identification of at-risk individuals. As aberrant hemispheric lateralization might precede overt depressive episodes, neurobiologically informed screening tools could revolutionize early intervention strategies, potentially averting chronic or recurrent depressive illness.

This research further opens the door to innovative pharmacological treatments designed with hemispheric lateralization dynamics in mind. By targeting neurotransmitter systems in a temporally precise manner or manipulating gene expression pathways linked to lateralization control, new classes of antidepressants or adjunctive therapies may emerge. Such precision medicine approaches stand to markedly improve the current 30-40% treatment resistance rates in major depressive disorder.

The DIRECT consortium’s work corroborates and extends earlier findings in neuropsychiatry, providing robust empirical data linking molecular neurobiology with macroscopic brain function. Their comprehensive, multimodal methodology sets a new standard for psychiatric research and underscores the necessity of integrating genetic, neurochemical, and neuroimaging data to fully capture the complexity of mental illness.

Importantly, the study challenges conventional frameworks that segregate brain lateralization studies from psychiatric research. By demonstrating dynamic lateralization shifts as a core feature of MDD, it argues convincingly for inclusion of lateralization metrics in both research paradigms and clinical protocols, fostering a holistic understanding of brain-behavior relationships in depression.

In conclusion, this landmark investigation by Ping, Sun, and colleagues manifests a paradigm-shifting view of major depressive disorder as a condition characterized by not static but dynamically shifting hemispheric lateralization, intricately orchestrated by neurotransmitter fluctuations and genetic predispositions. These insights herald a promising era where diagnostics, treatment, and preventive strategies are refined through the prism of brain lateralization dynamics, ultimately paving the way toward more effective management of one of humanity’s most pervasive and debilitating psychiatric illnesses.

Subject of Research: Dynamic changes in hemispheric lateralization in major depressive disorder and their correlation with neurotransmitter systems and genetic profiles.

Article Title: Dynamic changes in hemispheric lateralization in major depressive disorder correlate with neurotransmitter and genetic profiles: a DIRECT consortium study.

Article References:
Ping, LL., Sun, D., Sun, S. et al. Dynamic changes in hemispheric lateralization in major depressive disorder correlate with neurotransmitter and genetic profiles: a DIRECT consortium study. Transl Psychiatry (2025). https://doi.org/10.1038/s41398-025-03715-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03715-7

Depression, a pervasive psychiatric disorder affecting millions globally, has long posed substantial challenges to both clinicians and researchers due to the delayed onset and partial efficacy of traditional antidepressants. The discovery of agents capable of eliciting rapid antidepressant responses is thus of vital importance. NLX-101, as a highly selective and functionally biased 5-HT_1A receptor agonist, represents a new class of compounds that have exhibited fast-acting antidepressant properties in preclinical and early clinical studies. The mechanisms through which these rapid effects manifest, however, have remained elusive until now.

Employing [^18F]fluorodeoxyglucose positron emission tomography ([^18F]FDG PET), scientists were able to visualize the dynamic metabolic shifts induced by NLX-101 administration in rodent models. This imaging modality leverages the uptake of a radiolabeled glucose analog to map active brain regions engaged during various physiological and pathological states. By comparing metabolic activity pre- and post-treatment, researchers identified discrete alterations in glucose consumption that correlate with the therapeutic action of NLX-101.

The study reports that NLX-101 induces a rapid and region-specific increase in glucose metabolism within the medial prefrontal cortex (mPFC), a critical hub for executive function and emotional regulation. This augmented metabolic activity was detectable within an hour of administration, aligning temporally with observed behavioral improvements in depressive phenotypes. The enhanced mPFC functionality likely underpins the drug’s capability to rebalance dysfunctional neural circuits implicated in mood disorders.

Moreover, NLX-101’s effects extended beyond the mPFC, with significant metabolic modulations observed in the hippocampus and the dorsal raphe nucleus, both integral to serotonergic neurotransmission and neuroplasticity. These changes suggest that NLX-101 not only acts locally but also engages a broader network essential for mood stabilization and cognitive enhancement. The pattern of metabolic activation contrasts with that elicited by traditional antidepressants, which typically require weeks to generate comparable neural effects.

One particularly compelling aspect of the findings is the demonstration that NLX-101 selectively activates postsynaptic 5-HT_1A receptors without triggering autoreceptor-mediated feedback inhibition. This biased agonism circumvents the common drawback encountered with non-selective agonists, which often suppress serotonergic neuron firing and delay therapeutic onset. Consequently, NLX-101 achieves a more robust and immediate modulation of downstream signaling pathways involved in synaptic plasticity and neurogenesis.

Analyses of the metabolic data through advanced statistical parametric mapping elucidated the temporal progression of NLX-101’s neural actions. Initially focused on cortical excitation, subsequent phases involved progressive engagement of limbic structures, indicative of integrated network reorganization. Such measurable and time-resolved metabolic shifts provide invaluable biomarkers for both drug efficacy and mechanistic exploration, potentially guiding dose optimization and personalized treatment protocols.

Beyond its metabolic footprint, NLX-101’s mode of action implicates key intracellular cascades, such as the enhancement of brain-derived neurotrophic factor (BDNF) expression and modulation of glutamatergic signaling via AMPA receptor potentiation. These molecular events facilitate synaptic strengthening and contribute to rapid mood amelioration. The convergence of PET metabolic mapping and molecular biology thus paints a cohesive picture of rapid antidepressant action that melds systems neuroscience with cellular mechanisms.

Importantly, the study’s translational relevance is heightened by the use of [^18F]FDG PET, a clinically established imaging tool commonly deployed in human neuropsychiatric research. By mirroring this approach in animal models, the research lays critical groundwork for future human trials aimed at validating NLX-101’s efficacy and metabolic signatures in depressed patients. Such alignment enhances the potential for biomarker-driven clinical development, reducing time-to-market and improving therapeutic precision.

The comprehensive metabolic profiling afforded by this study challenges existing dogma regarding the necessity of prolonged treatment durations to achieve antidepressant effects. It beckons a reassessment of therapeutic strategies emphasizing rapid interventions capable of swiftly normalizing aberrant neural circuits. With NLX-101 demonstrating a reshaping of brain metabolism within minutes to hours, the prospect of immediate symptom relief moves closer to clinical reality.

While the results are promising, the researchers caution that further investigations are needed to delineate long-term neural adaptations and the impact on other neurotransmitter systems. Additionally, potential off-target effects and safety profiles must be scrupulously evaluated to ensure clinical viability. Nonetheless, the detailed metabolic insights derived set a robust scientific foundation for ongoing and future pharmacological innovation.

This study also underscores the utility of integrating neuroimaging biomarkers with behavioral assays to holistically assess antidepressant candidates. Correlating metabolic alterations with symptom alleviation offers a nuanced understanding far surpassing traditional endpoints reliant solely on behavioral metrics. Such multidimensional assessment frameworks may streamline the drug development pipeline by early identification of candidates with favorable neurobiological and clinical profiles.

In summary, the elucidation of [^18F]FDG PET metabolic patterns associated with the rapid antidepressant effects of NLX-101 opens exciting new vistas in neuropsychiatric therapeutics. By combining receptor-selective biased agonism with precision brain imaging, this research advances the quest for fast and effective treatments for depression. The implications resonate not only within psychopharmacology but also across broader neuroscientific efforts targeting brain network dysfunction.

As depression continues to impose a profound global health burden, the emergence of NLX-101 and its detailed metabolic characterization herald a new era of targeted, rapid-acting antidepressants. This advancement promises not only symptom relief but also deeper mechanistic insights into brain function and plasticity. Future clinical translation will be eagerly watched by the scientific and medical communities alike, potentially revolutionizing current standards of care.

The integration of advanced PET imaging and selective pharmacology exemplified in this study paves the way for personalized medicine approaches tailored to individual metabolic and receptor profiles. Such sophistication fosters optimism for overcoming historical treatment limitations and addressing the heterogeneity inherent in depressive disorders. Ultimately, this research epitomizes the power of multidisciplinary innovation at the intersection of molecular neuroscience, imaging technology, and psychiatric therapeutics.

Subject of Research: Rapid-acting antidepressant effects of NLX-101 and associated cerebral metabolic patterns assessed by [^18F]FDG PET imaging.

Article Title: [^18F]FDG PET metabolic patterns of the rapid-acting antidepressant effects of NLX-101, a 5-HT_1A receptor biased agonist.

Article References:
Chaib, S., Levigoureux, E., Bouvard, S. et al. [^18F]FDG PET metabolic patterns of the rapid-acting antidepressant effects of NLX-101, a 5-HT_1A receptor biased agonist. Transl Psychiatry 15, 336 (2025). https://doi.org/10.1038/s41398-025-03572-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03572-4

In the traditional clinical practice of TMS, clinicians have largely relied on historical reports linking lesion locations to behavioral or emotional symptoms, alongside neuroimaging studies highlighting dysfunction in frontal brain regions. This approach, while successful in many cases, necessarily narrows the scope of potential targets to a limited region of the brain—primarily the dorsolateral prefrontal cortex and adjacent prefrontal neuronal networks. These sites have been repeatedly validated as effective loci to alleviate symptoms in treatment-resistant depression and related illnesses. Yet, this focus raises the question: are there modifiable, posterior brain hubs implicated in psychiatric symptoms that remain unexplored by neuromodulation?

Emerging research suggests that the brain is a deeply interconnected organ, with psychiatric disorders reflecting dysfunction not only in frontal executive circuits but also in posterior regions such as the occipital cortex, precuneus, inferior parietal lobules, and cerebellum. These areas, traditionally associated with perceptual processes, self-referential thought, spatial cognition, and motor control, have gained recognition for their involvement in mood regulation, attention, and cognitive integration. Despite this, they have been conspicuously understudied as possible TMS targets in clinical trials, leaving a gap in both our understanding of neuropsychiatric circuitry and the full therapeutic potential of TMS.

In a timely and insightful Perspective article, McCalley and colleagues illuminate the landscape of posterior brain targets in neuropsychiatric disorders and propose an expansion of TMS paradigms. They argue that broadening target selection to incorporate these posterior regions could unlock novel therapeutic avenues that engage distinct neural networks, potentially offering relief for patients who are resistant to conventional prefrontal stimulation. This shift necessitates both a careful examination of the functional neuroanatomy involved and rigorous testing of safety and efficacy in future clinical settings.

The occipital cortex, long associated primarily with visual processing, has recently been implicated in affective disorders due to its connectivity with limbic and frontal brain regions. Neuroimaging studies have demonstrated altered activity patterns in the occipital lobe in individuals with depression and anxiety, revealing hyperconnectivity or hypoconnectivity that correlates with symptom severity. Targeting the occipital cortex with TMS could modulate early sensory processing, which in turn might influence higher-order cognitive and emotional circuits. Such an approach challenges the traditional focus on “executive” regions and underscores the role of sensory information processing in mood regulation.

Equally compelling is the precuneus, a central node in the default mode network (DMN), known for its role in self-referential thinking, episodic memory retrieval, and conscious awareness. Aberrant DMN activity has been robustly linked to depressive rumination and other maladaptive cognitive patterns seen in psychiatric illnesses. The precuneus’s accessibility to magnetic stimulation offers a tantalizing target to reshape network dynamics associated with negative self-focus, potentially alleviating persistent depressive symptoms or anxiety disorders. Early pilot studies hint at the feasibility of modulating this region noninvasively, though comprehensive clinical trials are warranted.

The inferior parietal lobules represent another posterior cortical area that holds therapeutic promise. These brain regions integrate multisensory information and contribute to attentional control and sensorimotor integration. Dysfunctions here have been observed in schizophrenia and mood disorders, where patients manifest aberrant perception, attentional bias, or impaired reality monitoring. By leveraging TMS to recalibrate activity in the inferior parietal lobules, clinicians may restore balance within distributed cortical networks, improving both cognitive and affective symptoms. However, the intricacy of this region’s functions requires precise targeting and modulation protocols to avoid undesired side effects.

Perhaps most intriguingly, the cerebellum—a structure historically relegated to motor coordination—has surfaced as a critical player in the regulation of emotion and cognition. The cerebellum is richly interconnected with the prefrontal cortex, limbic system, and associative sensory areas, and its involvement in psychiatric disorders such as depression, bipolar disorder, and autism spectrum conditions is increasingly recognized. Preliminary TMS studies have begun to explore cerebellar stimulation, noting possible benefits in mood stabilization and cognitive enhancement. This new frontier of neuromodulation could redefine therapeutic boundaries and challenge preconceived notions of localized brain function.

While posterior TMS targets offer exciting prospects, several technical and safety considerations must be addressed in their clinical implementation. The unique neuroanatomy and deeper cortical positioning of some posterior regions necessitate refined coil designs and stimulation parameters to achieve effective yet safe neuromodulation. In addition, the functional heterogeneity within posterior regions requires careful mapping to avoid off-target effects that could exacerbate symptoms or trigger unintended cognitive disruptions. Long-term studies will be critical to establish optimal dosing, session frequency, and durability of therapeutic gains.

Another challenge lies in integrating multi-modal imaging techniques, such as functional MRI, diffusion tensor imaging, and magnetoencephalography, to accurately identify suitable posterior targets based on individual neurocircuitry profiles. Personalized medicine approaches, combining advanced neuroimaging with computational modeling of electromagnetic field distribution, could tailor TMS protocols to each patient’s unique brain architecture. This precision medicine paradigm promises to maximize efficacy while minimizing adverse effects, heralding a new age in psychiatric treatment.

The few existing clinical trials investigating posterior TMS targets have yielded encouraging but preliminary results. Some studies targeting the occipital cortex have shown improvements in visual processing and mood symptoms, while cerebellar stimulation has demonstrated potential in enhancing executive function and reducing anxiety. These nascent data suggest that posterior TMS might complement or, in some cases, surpass traditional prefrontal approaches, especially for patients with resistant or atypical presentations. Nonetheless, replication in larger, randomized controlled studies remains an essential next step.

Combining posterior TMS targets with established prefrontal stimulation protocols could provide synergistic effects by engaging both sensory and executive neural networks. Multi-site stimulation paradigms might modulate dysfunctional connectivity more holistically than unilateral targeting, offering a richer therapeutic landscape. However, this complexity mandates careful clinical design to avoid overstimulation or desynchronization of critical neural circuits.

Ethically, expanding TMS beyond the frontal cortex compels the psychiatric community to balance innovation with caution. Given the emerging nature of posterior target research, informed consent processes must transparently communicate the experimental status of these interventions and potential unknown risks. Enhanced monitoring for adverse events and cognitive side effects will be necessary, alongside long-term follow-up to ascertain sustained benefits or late-emerging complications.

The consideration of posterior brain regions for neuromodulation reflects a broader paradigm shift in psychiatry—one that embraces the brain’s intrinsic network architecture rather than isolated loci. Modern psychiatric disorders are increasingly conceptualized as circuitopathies, involving complex interplay across distributed brain regions. TMS targeting posterior cortical and cerebellar nodes exemplifies this network-based approach, leveraging evolving neurobiological insights to refine therapeutic strategies.

In conclusion, the expansion of TMS applications to include posterior brain targets heralds a promising avenue for addressing unmet clinical needs in psychiatric treatment. While frontal lobe stimulation has established a robust therapeutic foundation, integrating occipital, parietal, precuneal, and cerebellar targets may enrich outcomes and offer new hope for patients with refractory conditions. Continued interdisciplinary collaboration among neuroscientists, clinicians, and engineers will be crucial to fully realize this potential and translate neuroanatomical discoveries into impactful, patient-centered therapies.

The contributions of McCalley et al. firmly anchor this emerging discussion in a rigorous scientific framework, emphasizing the importance of careful, methodical exploration of posterior neural hubs. Their Perspective calls on the psychiatric and neuromodulation communities to venture beyond conventional boundaries in pursuit of more comprehensive, network-oriented treatments. As research accelerates in this domain, TMS may well transform from a predominantly frontal cortex tool into an exquisite, multi-target instrument capable of reshaping the future of mental health care.

Subject of Research:
Transcranial magnetic stimulation targeting posterior brain regions for psychiatric disorder treatment.

Article Title:
Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex.

Article References:

McCalley, D.M., Sanderson, L.L., Dowdle, L.T. et al. Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex.
Nat. Mental Health (2025). https://doi.org/10.1038/s44220-025-00433-3

Image Credits: AI Generated